COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource

Status Completed

Clinical Trial Summary

COHIVE is an observational cohort nested in four antiretroviral therapy research studies (ADVANCE - NCT03122262; D²EFT - NCT03017872; DolPHIN2 - NCT03249181 and NAMSAL-ANRS12313 - NCT02777229). COHIVE will include participants who are possible COVID-19 cases with symptoms or confirmed COVID-19 cases, and participants who agree to have a serology testing for SARS-CoV-2 regardless of COVID-19 history.

Clinical Trial Description

COHIVE is an observational cohort study nested within four parent open label randomised clinical trials of first- and second-line antiretroviral therapies (ADVANCE - NCT03122262; D²EFT - NCT03017872; DolPHIN2 - NCT03249181 and NAMSAL-ANRS12313 - NCT02777229). COHIVE objective is to study the occurrence and outcomes of COVID-19 in people living with HIV across a variety of clinical settings. Taken together, these pivotal trials provide an established population and encompass a range of HIV therapies, HIV populations, and geographic regions to capture the full spectrum of these global public health emergency as it pertains to people living with HIV. The sample will include participants who are possible symptomatic or confirmed COVID-19 cases, and participants who agree to enrol in the SARS-CoV-2 seroprevalence cohort (regardless of SARS-CoV-2 infection). Approximately 2,500 participants are enrolled in these 4 studies. Enrolment into COHIVE substudy is voluntary and optional for participants in ADVANCE, D²EFT, DolPHIN2 and NAMSAL studies. Parameters relevant to COHIVE substudy including demographics, arm of randomised ART, medical and HIV history, immunological and virological results, adverse events at required time points will be collected as part of parent studies. Substudy specific assessments performed at baseline include optional sample collection for SARS-CoV-2 RT-PCR and serology; for the possible symptomatic or confirmed COVID-19 cases, the management of the patients, diagnostic test results, and outcomes, will be collected. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04371835
Study type	Observational
Source	Kirby Institute
Contact
Status	Completed
Phase
Start date	August 12, 2020
Completion date	December 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04369456` - Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients	N/A
Completed	`NCT04527471` - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19	Phase 2
Recruiting	`NCT04410510` - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19	Phase 2/Phase 3
Withdrawn	`NCT04383899` - Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
Completed	`NCT04542915` - COVID-19-Related Health and Practices Among Dental Hygienists
Not yet recruiting	`NCT04400019` - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)	Phase 2/Phase 3
Terminated	`NCT04954014` - Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients	Phase 2
Completed	`NCT04532632` - Taste and Smell Impairment in Critically Ill COVID-19 Patients
Suspended	`NCT04385771` - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	N/A
Terminated	`NCT04530448` - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization	Phase 4
Completed	`NCT04413435` - Clinical Characteristics of Critically Ill Patients With COVID-19
Terminated	`NCT05593770` - International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response	Phase 2/Phase 3
Completed	`NCT04510493` - Canakinumab in Patients With COVID-19 and Type 2 Diabetes	Phase 3
Active, not recruiting	`NCT04587219` - The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older	Phase 2
Withdrawn	`NCT05430958` - Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers	Phase 1
Completed	`NCT04596579` - SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
Completed	`NCT04405934` - COG-UK Project Hospital-Onset COVID-19 Infections Study	N/A
Enrolling by invitation	`NCT04484025` - SPI-1005 Treatment in Moderate COVID-19 Patients	Phase 2
Terminated	`NCT04442230` - NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)	Phase 2
Terminated	`NCT04642638` - Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms